MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ
4.420
-0.060
-1.34%
Opening 12:07 04/12 EDT
OPEN
4.480
PREV CLOSE
4.480
HIGH
4.480
LOW
4.360
VOLUME
3.77K
TURNOVER
0
52 WEEK HIGH
8.61
52 WEEK LOW
2.460
MARKET CAP
14.21M
P/E (TTM)
-1.6976
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EDSA last week (0401-0405)?
Weekly Report · 4d ago
RPT-BUZZ-PREVIEW: Conagra's shares sag ahead of results early Thurs
Conagra Brands Inc's CAG.N shares down 1.7% at $29.06 on Weds ahead of fiscal Q3 report due Thurs before market open. Wall Street concerned increased use of weight-loss drugs will crimp sales of U.S. Food companies. Analysts expect CAG to post a rev decline of 2.5% in Q3.
Reuters · 04/04 09:00
BUZZ-PREVIEW: Conagra's shares sag ahead of results early Thurs
Conagra Brands Inc's CAG.N shares down 1.7% at $29.06 on Weds ahead of fiscal Q3 report due Thurs before market open. The packaged foods firm's fiscal third quarter results are expected to be down 2.5%. Wall Street concerned increased use of weight-loss drugs will crimp sales.
Reuters · 04/03 17:58
Edesa Biotech Engages Investors at Global Conferences
TipRanks · 04/02 13:38
Weekly Report: what happened at EDSA last week (0325-0329)?
Weekly Report · 04/01 10:54
Weekly Report: what happened at EDSA last week (0318-0322)?
Weekly Report · 03/25 10:56
Edesa Biotech Shines at Autoimmune Conference
TipRanks · 03/22 04:37
Weekly Report: what happened at EDSA last week (0311-0315)?
Weekly Report · 03/18 10:55
More
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.

Webull offers Edesa Biotech Inc stock information, including NASDAQ: EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.